Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
a study on Breast Cancer
Triple Negative Breast Cancer (TNBC) Programmed Cell Death-1 (PD1, PD-1) Programmed Death-Ligand 1 (PDL1, PD-L1) Breast Neoplasms Triple Negative Breast Neoplasms Gemcitabine Paclitaxel Albumin-Bound Paclitaxel Carboplatin Pembrolizumab Nab-paclitaxel Normale Saline Solution
Lead Scientist at UCSF
- Hope Rugo
Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer.